XBiotech Company Insiders
| XBIT Stock | USD 3.82 0.02 0.53% |
XBiotech employs about 82 people. The company is managed by 6 executives with a total tenure of roughly 192 years, averaging almost 32.0 years of service per executive, having 13.67 employees per reported executive. Breaking down XBiotech's management performance can provide insight into the firm performance.
| John Simard Chairman Founder, Chairman, CEO and Pres |
XBiotech |
XBiotech's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with XBiotech's future performance. Based on our forecasts, it is anticipated that XBiotech will maintain a workforce of slightly above 80 employees by February 2025.XBiotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.1203) % which means that it has lost $0.1203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1575) %, meaning that it created substantial loss on money invested by shareholders. XBiotech's management efficiency ratios could be used to measure how well XBiotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.1 in 2025. Return On Capital Employed is likely to drop to -0.16 in 2025. At this time, XBiotech's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 209.4 M in 2025.Common Stock Shares Outstanding is likely to gain to about 36.4 M in 2025, despite the fact that Net Loss is likely to grow to (35.9 M).
XBiotech Workforce Comparison
XBiotech is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,787. XBiotech holds roughly 82.0 in number of employees claiming about 2.94% of equities under Health Care industry.
XBiotech Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XBiotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on XBiotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, XBiotech insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-03-01 | 1.0 | 1 | 1 | 100,000 | 0.00 |
| 2021-12-01 | 0.25 | 3 | 12 | 385,000 | 671,076 |
| 2021-09-01 | 0.1667 | 2 | 12 | 35,000 | 227,417 |
| 2021-03-01 | 0.1667 | 1 | 6 | 500,000 | 1,254,619 |
| 2020-09-01 | 1.0667 | 16 | 15 | 275,833 | 704,633 |
| 2020-03-01 | 0.0455 | 1 | 22 | 123,000 | 19,840,920 |
| 2019-12-01 | 4.0 | 4 | 1 | 1,360,000 | 185,000 |
| 2019-09-01 | 0.5 | 1 | 2 | 25,000 | 32,159 |
| 2019-03-01 | 5.5 | 11 | 2 | 212,400 | 9,000 |
| 2018-12-01 | 3.6667 | 11 | 3 | 133,940 | 435,000 |
| 2018-09-01 | 0.0588 | 1 | 17 | 15,000 | 207,841 |
| 2018-06-01 | 6.0 | 6 | 1 | 330,000 | 0.00 |
| 2018-03-01 | 1.25 | 5 | 4 | 130,000 | 88,201 |
| 2017-06-01 | 6.5 | 13 | 2 | 850,000 | 356,207 |
| 2016-12-01 | 1.5 | 3 | 2 | 168,440 | 144,573 |
| 2016-09-01 | 1.3333 | 4 | 3 | 150,427 | 20,427 |
| 2016-06-01 | 9.0 | 9 | 1 | 379,500 | 4,500 |
| 2016-03-01 | 1.6667 | 5 | 3 | 723,333 | 1,500,000 |
| 2015-12-01 | 0.35 | 7 | 20 | 88,600 | 135,600 |
| 2015-06-01 | 0.0909 | 1 | 11 | 70,368 | 1,062,000 |
XBiotech Notable Stakeholders
A XBiotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as XBiotech often face trade-offs trying to please all of them. XBiotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting XBiotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Simard | Founder, Chairman, CEO and Pres | Profile | |
| Benjamn Guzmn | Sr Fin | Profile | |
| Angela Hu | Principal Finance | Profile | |
| Lisa Simard | Inc USA | Profile | |
| Sushma Shivaswamy | Chief Officer | Profile | |
| BA CGA | VP Sec | Profile |
About XBiotech Management Performance
The success or failure of an entity such as XBiotech often depends on how effective the management is. XBiotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of XBiotech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the XBiotech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.15) | (0.16) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.10) | (0.11) |
Please note, the imprecision that can be found in XBiotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of XBiotech. Check XBiotech's Beneish M Score to see the likelihood of XBiotech's management manipulating its earnings.
XBiotech Workforce Analysis
Traditionally, organizations such as XBiotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare XBiotech within its industry.XBiotech Manpower Efficiency
Return on XBiotech Manpower
| Revenue Per Employee | 3.7K | |
| Revenue Per Executive | 50K | |
| Net Loss Per Employee | 299.5K | |
| Net Loss Per Executive | 4.1M | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 32.6M |
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.